Tubulin-targeting agents in hybrid drugs

Current Medicinal Chemistry

Volumn 17, Issue 7, 2010, Pages 609-639

  Breen, E C ^a   Walsh, J J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Anti cancer; Chemotherapy; Combination therapy; Hybrid; Microtubules; Resistance; Tubulin

Indexed keywords

AC 7739; ADAMANTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CETUXIMAB; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ELSIDINE; EPIPODOPHYLLOTOXIN DERIVATIVE; ESPERAMICIN; FILDESIN; GLYCYRRHETINIC ACID; IXABEPILONE; MELPHALAN; METHOTREXATE; NAVELBINE; NILUTAMIDE; OCTREOTIDE; PACLITAXEL; PREDNISOLONE; TAXANE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG CONJUGATION; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; NEOPLASMS; TUBULIN; TUBULIN MODULATORS;

EID: 77950654528     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790416254     Document Type: Review

References (161)

1. Amos, L. A. Microtubule structure and its stabilisation. Org. Biomol. Chem., 2004, 2, 2153-2160
2. Pellegrini, F.; Budman, D. R. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest., 2005, 23, 264-273
3. Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res., 2004, 10, 415-427 (Pubitemid 38173977)
4. Denekamp, J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer, 1982, 45, 136-139 (Pubitemid 12207761)
5. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 1990, 9, 267-282 (Pubitemid 20380383)
6. Denekamp, J.; Hobson, B. Endothelial-cell proliferation in experimental tumours. Br. J. Cancer, 1982, 46, 711-720
7. Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer, 1999, 81, 1318-1327
8. Galbraith, S. M.; Chaplin, D. J.; Lee, F.; Stratford, M. R.; Locke, R. J.; Vojnovic, B.; Tozer, G. M. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res., 2001, 21, 93-102.
9. Kanthou, C.; Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood, 2002, 99, 2060-2069
10. Downing, K. H. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu. Rev. Cell. Dev. Biol., 2000, 16, 89-111.
11. Jordan, M. A.; Margolis, R. L.; Himes, R. H.; Wilson, L. Identification of a distinct class of vinblastine binding sites on microtubules. J. Mol. Biol., 1986, 187, 61-73. (Pubitemid 16065316)
12. Rai, S. S.; Wolff, J. Localization of the vinblastine-binding site on beta-tubulin. J. Biol. Chem., 1996, 271, 14707-14711
13. Gigant, B.; Wang, C.; Ravelli, R.; Roussi, F.; Steinmetz, M.; Curmi, P.; Sobel, A.; Knossow, M. Structural basis for the regulation of tubulin by vinblastine. Nature, 2005, 435, 519-522. (Pubitemid 40734250)
14. Nogales, E.; Wolf, S. G.; Downing, K. H. Structure of the alpha beta tubulin dimer by electron crystallography. Nature, 1998, 391, 199-203.
15. Rao, S.; He, L.; Chakravarty, S.; Ojima, I.; Orr, G. A.; Horwitz, S. B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J. Biol. Chem., 1999, 274, 37990-37994
16. Rao, S.; Krauss, N. E.; Heerding, J. M.; Swindell, C. S.; Ringel, I.; Orr, G. A.; Horwitz, S. B. 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J. Biol. Chem., 1994, 269, 3132-3134 (Pubitemid 2044957)
17. Rao, S.; Orr, G. A.; Chaudhary, A. G.; Kingston, D. G.; Horwitz, S. B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J. Biol. Chem., 1995, 270, 20235-20238
18. Snyder, J. P.; Nettles, J. H.; Cornett, B.; Downing, K. H.; Nogales, E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 5312-5316 (Pubitemid 32397125)
19. Bai, R.; Pei, X. F.; Boye, O.; Getahun, Z.; Grover, S.; Bekisz, J.; Nguyen, N. Y.; Brossi, A.; Hamel, E. Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine. J. Biol. Chem., 1996, 271, 12639-12645 (Pubitemid 26160939)
20. Ravelli, R. B.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature, 2004, 428, 198-202. (Pubitemid 38374318)
21. Uppuluri, S.; Knipling, L.; Sackett, D. L.; Wolff, J. Localization of the colchicine-binding site of tubulin. Proc. Natl. Acad. Sci. U S A, 1993, 90, 11598-11602
22. Clement, M. J.; Rathinasamy, K.; Adjadj, E.; Toma, F.; Curmi, P. A.; Panda, D. Benomyl and colchicine synergistically inhibit cell proliferation and mitosis: evidence of distinct binding sites for these agents in tubulin. Biochemistry, 2008, 47, 13016-13025
23. Gupta, K.; Bishop, J.; Peck, A.; Brown, J.; Wilson, L.; Panda, D. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin. Biochem., 2004, 43, 6645-6655 (Pubitemid 38697564)
24. MacDonald, L. M.; Armson, A.; Thompson, A. R.; Reynoldson, J. A. Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol. Biochem. Parasitol., 2004, 138, 89-96.
25. Yenjerla, M.; Cox, C.; Wilson, L.; Jordan, M. A. Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics. J. Pharmacol. Exp. Ther., 2009, 328, 390-398
26. Bourdron, J.; Barbier, P.; Allegro, D.; Villard, C.; Lafitte, D.; Commeiras, L.; Parrain, J. L.; Peyrot, V. Caulerpenyne binding to tubulin: structural modifications by a non conventional pharmacological agent. Med. Chem., 2009, 5, 182-190
27. Morrissette, N. S.; Mitra, A.; Sept, D.; Sibley, L. D. Dinitroanilines bind alpha-tubulin to disrupt microtubules. Mol. Biol. Cell, 2004, 15, 1960-1968
28. Bai, R. L.; Paull, K. D.; Herald, C. L.; Malspeis, L.; Pettit, G. R.; Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem., 1991, 266, 15882-15889
29. Liu, J.; Towle, M. J.; Cheng, H.; Saxton, P.; Reardon, C.; Wu, J.; Murphy, E. A.; Kuznetsov, G.; Johannes, C. W.; Tremblay, M. R.; Zhao, H.; Pesant, M.; Fang, F. G.; Vermeulen, M. W.; Gallagher, B. M., Jr.; Littlefield, B. A. In vitro and in vivo anticancer activities of synthetic (-)-laulimalide, a marine natural product microtubule stabilizing agent. Anticancer Res., 2007, 27, 1509-1518
30. Dutcher, J. P.; Novik, Y.; O'Boyle, K.; Marcoullis, G.; Secco, C.; Wiernik, P. H. 20th-century advances in drug therapy in oncology - Part. II. J. Clin. Pharmacol., 2000, 40, 1079-1092.
31. Pizzocaro, G.; Salvioni, R.; Pasi, M.; Zanoni, F.; Milani, A.; Pilotti, S.; Monfardini, S. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage III and bulky stage II nonseminomatous testicular cancer. Cancer, 1985, 56.
32. Joel, S. The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use? Cancer Treat. Rev., 1995, 21, 513-525. (Pubitemid 26128923)
33. + etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials, 2007, 28, 3724-3730.
34. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 2005, 23, 7794-7803 (Pubitemid 46657376)
35. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 1995, 55, 2325-2333
36. Greenberger, L. M.; Lothstein, L.; Williams, S. S.; Horwitz, S. B. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 3762-3766
37. Freedman, H.; Huzil, J.; Luchko, T.; Luduen a, R.; Tuszynski, J. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J. Chem. Inf. Model, 2009, 49, 424-436.
38. 2-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inf., 3.
39. Maksymiuk, A. W.; Jett, J. R.; Earle, J. D.; Su, J. Q.; Diegert, F. A.; Mailliard, J. A.; Kardinal, C. G.; Krook, J. E.; Veeder, M. H.; Wiesenfeld, M. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J. Clin. Oncol., 1994, 12, 70.
40. Shirasaka, T.; Shimamoto, Y.; Ohshimo, H.; Saito, H.; Fukushima, M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer chemo. Pharmacol., 1993, 32, 167-172. (Pubitemid 23146807)
41. Fox, S. B.; Gatter, K. C.; Bicknell, R.; Going, J. J.; Stanton, P.; Cooke, T. G.; Harris, A. L. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res., 1993, 53, 4161-4163 (Pubitemid 24146759)
42. Siemann, D. W.; Chaplin, D. J.; Horsman, M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer, 2004, 100, 2491-2499 (Pubitemid 38715753)
43. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumour blood vessels. Nat Rev Cancer, 2005, 5, 423-435
44. Shaked, Y.; Ciarrocchi, A.; Franco, M.; Lee, C. R.; Man, S.; Cheung, A. M.; Hicklin, D. J.; Chaplin, D.; Foster, F. S.; Benezra, R.; Kerbel, R. S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science, 2006, 313, 1785-1787 (Pubitemid 44454154)
45. Siemann, D. W.; Mercer, E.; Lepler, S.; Rojiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer, 2002, 99, 1-6.
46. Chow, L. M.; Chan, T. H. Novel classes of dimer antitumour drug candidates. Curr. Pharm. Des., 2009, 15, 659-674
47. Mammen, M.; Choi, S. K.; Whitesides, G. M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem.. Int. Ed., 1998, 37, 2755-2794.
48. Kim, J. W.; Lee, H. S. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model. Int. J. Mol. Med., 2004, 14, 529-535
49. Mukhopadhyay, S.; Barnes, C. M.; Haskel, A.; Short, S. M.; Barnes, K. R.; Lippard, S. J. Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature. Bioconjug. Chem., 2008, 19, 39-49.
50. Myrberg, H.; Zhang, L.; Mae, M.; Langel, U. Design of a tumor-homing cell-penetrating peptide. Bioconjug. Chem., 2008, 19, 70-75
51. Temming, K.; Meyer, D. L.; Zabinski, R.; Dijkers, E. C.; Poelstra, K.; Molema, G.; Kok, R. J. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjug. Chem., 2006, 17, 1385-1394
52. Dorr, R. T. Pharmacology and toxicology of Cremophor EL diluent. Ann. Pharmacother., 1994, 28, S11-4.
53. Sharma, A.; Mayhew, E.; Bolcsak, L.; Cavanaugh, C.; Harmon, P.; Janoff, A.; Bernacki, R. J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer, 1997, 71, 103-107
54. Sparreboom, A.; van Zuylen, L.; Brouwer, E.; Loos, W. J.; de Bruijn, P.; Gelderblom, H.; Pillay, M.; Nooter, K.; Stoter, G.; Verweij, J. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res., 1999, 59, 1454-1457 (Pubitemid 29160110)
55. Attard, G.; Greystoke, A.; Kaye, S.; De Bono, J. Update on tubulin-binding agents. Pathol. Biol. (Paris), 2006, 54, 72-84.
56. Chipman, S. D.; Oldham, F. B.; Pezzoni, G.; Singer, J. W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed., 2006, 1, 375-383
57. Hu, G. G.; Shui, X.; Leng, F.; Priebe, W.; Chaires, J. B.; Williams, L. D. Structure of a DNA-bisdaunomycin complex. Biochem., 1997, 36, 5940-5946
58. Kar, A. K.; Braun, P. D.; Wandless, T. J. Synthesis and evaluation of daunorubicin-paclitaxel dimers. Bioorg. Med. Chem. Lett., 2000, 10, 261-264
59. Guy, R.; Scott, Z.; Sloboda, R.; Nicolaou, K. Fluorescent taxoids. Chem. Biol., 1996, 3, 1021-1031
60. Marco, A.; Arcamone, F. DNA complexing antibiotics: daunomycin, adriamycin and their derivatives. Arzneimittelforschung, 1975, 25, 368-74.
61. Lamberts, S. W.; Krenning, E. P.; Klijn, J. G.; Reubi, J. C. The clinical use of somatostatin analogues in the treatment of cancer. Baillieres Clin. Endocrinol. Metab., 1990, 4, 29-49.
62. Bajetta, E.; Procopio, G.; Ferrari, L.; Martinetti, A.; Zilembo, N.; Catena, L.; Alu, M.; Della, T. S.; Alberti, D.; Buzzoni, R. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer, 2002, 94, 299-304. (Pubitemid 34081357)
63. Bolanowski, M.; Jarzab, B.; Handkiewicz-Junak, D.; Jeziorski, A.; Kos-Kudla, B.; Zajecki, W. [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. Endokrynol. Pol., 2008, 59, 87-96.
64. Bontenbal, M.; Foekens, J. A.; Lamberts, S. W.; de Jong, F. H.; van Putten, W. L.; Braun, H. J.; Burghouts, J. T.; van der Linden, G. H.; Klijn, J. G. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br. J. Cancer, 1998, 77, 115-122
65. Dolan, J. T.; Miltenburg, D. M.; Granchi, T. S.; Miller, C. C., 3rd; Brunicardi, F. C. Treatment of metastatic breast cancer with somatostatin analogues - a meta-analysis. Ann. Surg. Oncol., 2001, 8, 227-233
66. Ingle, J. N.; Kardinal, C. G.; Suman, V. J.; Krook, J. E.; Hatfield, A. K. Octreotide as first-line treatment for women with metastatic breast cancer. Invest. New Drugs, 1996, 14, 235-237 (Pubitemid 26340695)
67. Warner, R. R.; Mani, S.; Profeta, J.; Grunstein, E. Octreotide treatment of carcinoid hypertensive crisis. Mt. Sinai J. Med., 1994, 61, 349-355 (Pubitemid 24311064)
68. Zarina, A. L.; Hamidah, A.; Zulkifli, S. Z.; Zulfiqar, M. A.; Jamal, R. Malignant pancreatic carcinoid tumour. Singapore Med. J., 2007, 48, e320-2.
69. Lamberts, S. W.; Krenning, E. P.; Reubi, J. C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev., 1991, 12, 450-482
70. Lamberts, S. W.; Reubi, J. C.; Krenning, E. P. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin. Oncol., 1994, 21, 1-5. (Pubitemid 24378898)
71. Weckbecker, G.; Raulf, F.; Tolcsvai, L.; Bruns, C. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion, 1996, 57 Suppl. 1, 22-28 (Pubitemid 26183914)
72. Huang, C. M.; Wu, Y. T.; Chen, S. T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol., 2000, 7, 453-461
73. Wittman, M. D.; Kadow, J. F.; Vyas, D. M.; Lee, F. L.; Rose, W. C.; Long, B. H.; Fairchild, C.; Johnston, K. Synthesis and antitumor activity of novel paclitaxel-chlorambucil hybrids. Bioorg. Med. Chem. Lett., 2001, 11, 811-814. (Pubitemid 32230686)
74. Shi, Q.; Wang, H. K.; Bastow, K. F.; Tachibana, Y.; Chen, K.; Lee, F. Y.; Lee, K. H. Antitumor agents 210. Synthesis and evaluation of taxoid-epipodophyllotoxin conjugates as novel cytotoxic agents. Bioorg. Med. Chem., 2001, 9, 2999-3004. (Pubitemid 32904545)
75. Ohtsu, H.; Nakanishi, Y.; Bastow, K. F.; Lee, F. Y.; Lee, K. H. Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents. Bioorg. Med. Chem., 2003, 11, 1851-1857 (Pubitemid 36349166)
76. Wang, H. K.; Liu, S. Y.; Hwang, K. M.; Taylor, G.; Lee, K. H. Synthesis of novel water-soluble 7-(aminoacylhydrazono)-formyl camptothecins with potent inhibition of DNA topoisomerase I. Bioorg. Med. Chem., 1994, 2, 1397-1402
77. Nakagawa-Goto, K.; Nakamura, S.; Bastow, K. F.; Nyarko, A.; Peng, C.-Y.; Lee, F.-Y.; Lee, F.-C.; Lee, K.-H. Antitumor agents. 256. Conjugation of paclitaxel with other antitumor agents: Evaluation of novel conjugates as cytotoxic agents. Bioorg. Med. Chem. Lett., 2007, 17, 2894-2898. (Pubitemid 46656458)
78. Kratz, F.; Abu Ajaj, K.; Warnecke, A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Investig. Drugs, 2007, 16, 1037-1058 (Pubitemid 47074159)
79. Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy. ChemMedChem., 2008, 3, 20-53.
80. Mehvar, R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr. Pharm. Biotechnol., 2003, 4, 283-302. (Pubitemid 37220861)
81. Ulbrich, K.; Subr, V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Deliv. Rev., 2004, 56, 1023-1050 (Pubitemid 38520207)
82. Kratz, F.; Muller-Driver, R.; Hofmann, I.; Drevs, J.; Unger, C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem., 2000, 43, 1253-1256 (Pubitemid 30212566)
83. Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Druckes, P.; Esser, N.; Drevs, J.; Rognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J. Med. Chem., 2002, 45, 5523-5533 (Pubitemid 35424970)
84. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release, 2000, 65, 271-284 (Pubitemid 30122932)
85. Amato, R. J.; Sarao, H. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer. Clin. Genitourin. Cancer, 2006, 4, 281-286 (Pubitemid 43779886)
86. Zielinski, C. C. Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer. Oncology (Williston Park), 2003, 17, 36-40.
87. Shimada, M.; Kigawa, J.; Terakawa, N.; Yoshizaki, A.; Shoji, T.; Suzuki, M.; Hatae, M.; Tsuda, H.; Ohwada, M.; Sugiyama, T. Phase I trial of paclitaxel, doxorubicin, and carboplatin (TAC) for the treatment of endometrial cancer. Int. J. Gynecol. Cancer, 2007, 17, 210-214 (Pubitemid 46213992)
88. Ajaj, K. A.; Biniossek, M. L.; Kratz, F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. Bioconjug. Chem., 2009, 20, 390-396
89. Schmid, B.; Chung, D. E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug. Chem., 2007, 18, 702-716 (Pubitemid 47010789)
90. Dubowchik, G. M.; Firestone, R. A.; Padilla, L.; Willner, D.; Hofstead, S. J.; Mosure, K.; Knipe, J. O.; Lasch, S. J.; Trail, P. A. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem., 2002, 13, 855-869
91. McGown, A. T.; Fox, B. W. Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. Cancer Chemother. Pharmacol., 1990, 26, 79-81. (Pubitemid 20122896)
92. Coggiola, B.; Pagliai, F.; Allegrone, G.; Genazzani, A. A.; Tron, G. C. Synthesis and biological activity of mustard derivatives of combretastatins. Bioorg. Med. Chem. Lett., 2005, 15, 3551-3554 (Pubitemid 40942053)
93. Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol., 2002, 83, 21-38. (Pubitemid 34638944)
94. Harrell, J. M.; Murphy, P. J.; Morishima, Y.; Chen, H.; Mansfield, J. F.; Galigniana, M. D.; Pratt, W. B. Evidence for glucocorticoid receptor transport on microtubules by dynein. J. Biol. Chem., 2004, 279, 54647-54654
95. Sharifi, N.; Hamel, E.; Lill, M. A.; Risbood, P.; Kane, C. T., Jr.; Hossain, M. T.; Jones, A.; Dalton, J. T.; Farrar, W. L. A bifunctional colchicinoid that binds to the androgen receptor. Mol. Cancer Ther., 2007, 6, 2328-2336 (Pubitemid 47294761)
96. Estebanez-Perpina, E.; Moore, J. M.; Mar, E.; Delgado-Rodrigues, E.; Nguyen, P.; Baxter, J. D.; Buehrer, B. M.; Webb, P.; Fletterick, R. J.; Guy, R. K. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J. Biol. Chem., 2005, 280, 8060-8068
97. Berg, U.; Deinum, J.; Lincoln, P.; Kvassman, J. Stereochemistry of colchicinoids. Enantiomeric stability and binding to tubulin of desacetamidocolchicine and desacetamidoisocolchicine. Bioorg. Chem., 1991, 19, 53-65.
98. Cogan, P. S.; Koch, T. H. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate. J. Med. Chem., 2003, 46, 5258-5270
99. Christiansen, R. G.; Bell, M. R.; D'Ambra, T. E.; Mallamo, J. P.; Herrmann, J. L.; Ackerman, J. H.; Opalka, C. J.; Kullnig, R. K.; Winneker, R. C.; Snyder, B. W.; et al. Antiandrogenic steroidal sulfonylpyrazoles. J. Med. Chem., 1990, 33, 2094-2100
100. Gastpar, R.; Goldbrunner, M.; Marko, D.; von Angerer, E. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem., 1998, 41, 4965-4972
101. Kaufmann, D.; Pojarová, M.; Vogel, S.; Liebl, R.; Gastpar, R.; Gross, D.; Nishino, T.; Pfaller, T.; von Angerer, E. Antimitotic activities of 2-phenylindole-3-carbaldehydes in human breast cancer cells. Bioorg. Med. Chem., 2007, 15, 5122-5136. (Pubitemid 46880379)
102. Vogel, S.; Kaufmann, D.; Pojarova, M.; Muller, C.; Pfaller, T.; Kuhne, S.; Bednarski, P. J.; von Angerer, E. Aroyl hydrazones of 2-phenylindole-3- carbaldehydes as novel antimitotic agents. Bioorg. Med. Chem., 2008, 16, 6436-6447
103. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science, 2002, 296, 1655-1657.
104. Opel, D.; Westhoff, M. A.; Bender, A.; Braun, V.; Debatin, K. M.; Fulda, S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res., 2008, 68, 6271-6280
105. Hall, I. H.; Lee, K. H.; Starnes, C. O.; Eigebaly, S. A.; Ibuka, T.; Wu, Y. S.; Kimura, T.; Haruna, M. Antitumor agents XXX: Evaluation of alpha-methylene-gamma-lactone-containing agents for inhibition of tumor growth, respiration, and nucleic acid synthesis. J. Pharm. Sci., 1978, 67, 1235-1239
106. Zhang, S.; Won, Y. K.; Ong, C. N.; Shen, H. M. Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents, 2005, 5, 239-249
107. Zhang, C.; Yang, N.; Yang, C. H.; Ding, H. S.; Luo, C.; Zhang, Y.; Wu, M. J.; Zhang, X. W.; Shen, X.; Jiang, H. L.; Meng, L. H.; Ding, J. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton. PLoS ONE, 2009, 4, 4881.
108. Danieli, B.; Giardini, A.; Lesma, G.; Passarella, D.; Silvani, A.; Appendino, G.; Noncovich, A.; Fontana, G.; Bombardelli, E.; Sterner, O. Synthesis and biological evaluation of paclitaxel-thiocolchicine hybrids. Chem. Biodivers., 2004, 1, 327-345
109. Airoldi, M.; Cortesina, G.; Giordano, C.; Pedani, F.; Bumma, C.; Gabriele, P. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med. Oncol., 2003, 20, 19-24. (Pubitemid 36344021)
110. Di Lorenzo, G.; Pizza, C.; Autorino, R.; De Laurentiis, M.; Marano, O.; D'Alessio, A.; Cancello, G.; Altieri, V.; Tortora, G.; Perdona, S.; Bianco, A. R.; De Placido, S. Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. Eur. Urol., 2004, 46, 712-716 (Pubitemid 39488399)
111. Dieras, V.; Fumoleau, P.; Bourgeois, H.; Misset, J. L.; Azli, N.; Pouillart, P. Taxoids in combination chemotherapy for metastatic breast cancer. Anticancer Drugs, 1996, 7 Suppl. 2, 47-52. (Pubitemid 26275624)
112. Mayordomo, J. I.; Milla, A.; Morales, S.; Yubero, A.; Lorenzo, A.; Baena, J. M.; Modolell, A.; Sanz, J.; Illarramendi, J.; Garcia, M. J.; Machengs, I.; Burrilo, M. A.; Tres, A. Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer. Clin. Breast Cancer, 2004, 5, 131-135 (Pubitemid 39029205)
113. Giannakakou, P.; Villalba, L.; Li, H.; Poruchynsky, M.; Fojo, T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer, 1998, 75, 57-63. (Pubitemid 28113978)
114. Taraboletti, G.; Micheletti, G.; Dossi, R.; Borsotti, P.; Martinelli, M.; Fiordaliso, F.; Ryan, A. J.; Giavazzi, R. Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin. Cancer Res., 2005, 11, 2720-2726 (Pubitemid 40569474)
115. Bombuwala, K.; Kinstle, T.; Popik, V.; Uppal, S. O.; Olesen, J. B.; Vina, J.; Heckman, C. A. Colchitaxel, a coupled compound made from microtubule inhibitors colchicine and paclitaxel. Beilstein J. Org. Chem., 2006, 2, 13.
116. Zefirova, O. N.; Nurieva, E. V.; Lemcke, H.; Ivanov, A. A.; Shishov, D. V.; Weiss, D. G.; Kuznetsov, S. A.; Zefirov, N. S. Design, synthesis, and bioactivity of putative tubulin ligands with adamantane core. Bioorg. Med. Chem. Lett., 2008, 18, 5091-5094.
117. Danieli, B.; Giardini, A.; Lesma, G.; Passarella, D.; Peretto, B.; Sacchetti, A.; Silvani, A.; Pratesi, G.; Zunino, F. Thiocolchicine- podophyllotoxin conjugates: dynamic libraries based on disulfide exchange reaction. J. Org. Chem., 2006, 71, 2848-2853
118. Passarella, D.; Giardini, A.; Peretto, B.; Fontana, G.; Sacchetti, A.; Silvani, A.; Ronchi, C.; Cappelletti, G.; Cartelli, D.; Borlak, J.; Danieli, B. Inhibitors of tubulin polymerization: synthesis and biological evaluation of hybrids of vindoline, anhydrovinblastine and vinorelbine with thiocolchicine, podophyllotoxin and baccatin III. Bioorg. Med. Chem., 2008, 16, 6269-6285 (Pubitemid 351758817)
119. Lu, Y. F.; Harwig, C. W.; Fallis, A. G. Taxamycins: a new enediyne family constructed from versatile disilyl-substituted building blocks. J. Org. Chem., 1993, 58, 4202-4204.
120. Lu, Y. F.; Harwig, C. W.; Fallis, A. G. Taxamycins: a new enediyne family with synthetic and biological potential. Can. J. Chem., 1995, 73, 2253-2262.
121. Py, S.; Harwig, C. W.; Banerjee, S.; Brown, D. L.; Fallis, A. G. Taxamycin studies: Synthesis of taxoid-calicheamicin hybrids. Tetrahedron Lett., 1998, 39, 6139-6142.
122. Ojima, I.; Chakravarty, S.; Inoue, T.; Lin, S.; He, L.; Horwitz, S. B.; Kuduk, S. D.; Danishefsky, S. J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. U S A, 1999, 96, 4256-4261
123. Ojima, I.; Lin, S.; Inoue, T.; Miller, M. L.; Borella, C. P.; Geng, X.; Walsh, J. J. Macrocycle formation by ring-closing metathesis. Application to the syntheses of novel macrocyclic taxoids. J. Am. Chem. Soc., 2000, 122, 5343-5353.
124. Janik, M. E.; Bane, S. L. Synthesis and antimicrotubule activity of combretatropone derivatives. Bioorg. Med. Chem., 2002, 10, 1895-1903 And references cited.
125. Rossi, M.; Gorbunoff, M. J.; Caruso, F.; Wing, B.; Perez-Ramirez, B.; Timasheff, S. N. Structural analysis of the substoichiometric and stoichiometric microtuble-inhibiting biphenyl analogues of colchicine. Biochemistry, 1996, 35, 3286-3289 (Pubitemid 26082257)
126. Staretz, M. E.; Hastie, S. B. Synthesis and tubulin binding of novel C-10 analogues of colchicine. J. Med. Chem., 1993, 36, 758-764
127. Hahn, K. M.; Humphreys, W. G.; Helms, A. M.; Hastie, S. B.; Macdonald, T. L. Structural requirements for the binding of colchicine analogs to tubulin: the role of the C-10 substituent. Bioorg. Med. Chem. Lett., 1991, 1, 471-476.
128. Menendez, M.; Laynez, J.; Medrano, F. J.; Andreu, J. M. A thermodynamic study of the interaction of tubulin with colchicine site ligands. J. Biol. Chem., 1989, 264, 16367-16371
129. Barbier, P.; Guise, S.; Huitorel, P.; Amade, P.; Pesando, D.; Briand, C.; Peyrot, V. Caulerpenyne from Caulerpa taxifolia has an antiproliferative activity on tumor cell line SK-N-SH and modifies the microtubule network. Life Sci., 2001, 70, 415-429. (Pubitemid 34017536)
130. Commeiras, L.; Bourdron, J.; Douillard, S.; Barbier, P.; Vanthuyne, N.; Peyrot, V.; Parrain, J. Total Synthesis of Terpenoids Isolated from Caulerpale Algae and Their Inhibition of Tubulin Assembly. Synthesis, 2006, 1, 166.
131. Bourdron, J.; Commeiras, L.; Barbier, P.; Bourgarel-Rey, V.; Pasquier, E.; Vanthuyne, N.; Hubaud, J. C.; Peyrot, V.; Parrain, J. L. Caulerpenyne-colchicine hybrid: synthesis and biological evaluation. Bioorg. Med. Chem., 2006, 14, 5540-5548 (Pubitemid 43996987)
132. Bailly, C. Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids. Curr. Med. Chem. Anti-Cancer Agents, 2004, 4, 363.
133. Banwell, M. G.; Hamel, E.; Hockless, D. C. R.; Verdier-Pinard, P.; Willis, A. C.; Wong, D. J. 4, 5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: Synthesis and evaluation as anti-mitotic and cytotoxic agents. Bioorg. Med. Chem., 2006, 14, 4627-4638.
134. Lawrence, N. J.; McGown, A. T. The chemistry and biology of antimitotic chalcones and related enone systems. Curr. Pharm. Des., 2005, 11, 1679-1693
135. Nam, N. H.; Byung-Zun, A. Combretastatin-chalcone hybrids: synthesis and cytotoxicity. Med. Chem., 2007, 3, 373-377
136. Cormier, A.; Marchand, M.; Ravelli, R. B.; Knossow, M.; Gigant, B. Structural insight into the inhibition of tubulin by vinca domain peptide ligands. EMBO Rep., 2008, 9, 1101-1106
137. Ngo, Q. A.; Roussi, F.; Cormier, A.; Thoret, S.; Knossow, M.; Guenard, D.; Gueritte, F. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids. J. Med. Chem., 2009, 52, 134-142
138. Kerksiek, K.; Mejillano, M. R.; Schwartz, R. E.; Georg, G. I.; Himes, R. H. Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett., 1995, 377, 59-61.
139. White, J. D.; Smits, H.; Hamel, E. Synthesis of cryptothilone 1, the first cryptophycin-epothilone hybrid. Org. Lett., 2006, 8, 3947-3950 (Pubitemid 44432827)
140. Paterson, I.; Britton, R.; Delgado, O.; Wright, A. E. Stereochemical determination of dictyostatin, a novel microtubule-stabilising macrolide from the marine sponge Corallistidae sp. Chem. Commun. (Camb.), 2004, 632-633
141. Buey, R. M.; Barasoain, I.; Jackson, E.; Meyer, A.; Giannakakou, P.; Paterson, I.; Mooberry, S.; Andreu, J. M.; Diaz, J. F. Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem. Biol., 2005, 12, 1269-1279
142. Isbrucker, R. A.; Cummins, J.; Pomponi, S. A.; Longley, R. E.; Wright, A. E. Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem. Pharmacol., 2003, 66, 75-82.
143. ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longley, R. E.; Gunasekera, S. P.; Rosenkranz, H. S.; Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry, 1996, 35, 243-250
144. Shin, Y.; Choy, N.; Turner, T. R.; Balachandran, R.; Madiraju, C.; Day, B. W.; Curran, D. P. Discodermolide/Dictyostatin hybrids: synthesis and biological evaluation. Org. Lett., 2002, 4, 4443-4446
145. Paterson, I.; Gardner, N. M. Design, synthesis and biological evaluation of a macrocyclic discodermolide/dictyostatin hybrid. Chem. Commun. (Camb.), 2007, 49-51. (Pubitemid 44913083)
146. Paterson, I.; Naylor, G. J.; Wright, A. E. Total synthesis of a potent hybrid of the anticancer natural products dictyostatin and discodermolide. Chem. Commun. (Camb.), 2008, 4628-4630
147. Loganzo, F.; Discafani, C. M.; Annable, T.; Beyer, C.; Musto, S.; Hari, M.; Tan, X.; Hardy, C.; Hernandez, R.; Baxter, M.; Singanallore, T.; Khafizova, G.; Poruchynsky, M. S.; Fojo, T.; Nieman, J. A.; Ayral-Kaloustian, S.; Zask, A.; Andersen, R. J.; Greenberger, L. M. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res., 2003, 63, 1838-1845
148. Zask, A.; Kaplan, J.; Musto, S.; Loganzo, F. Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. J.
149. Romagnoli, R.; Baraldi, P. G.; Carrion, M. D.; Cruz-Lopez, O.; Cara, C. L.; Balzarini, J.; Hamel, E.; Canella, A.; Fabbri, E.; Gambari, R.; Basso, G.; Viola, G. Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2009, 19, 2022-2028
150. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem. Biol., 2006, 1, 279-284
151. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol., 2004, 11, 775-785
152. Gaukroger, K.; Hadfield, J. A.; Lawrence, N. J.; Nolan, S.; McGown, A. T. Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit? Org. Biomol. Chem., 2003, 1, 3033-3037
153. Knox, A. J.; Price, T.; Pawlak, M.; Golfis, G.; Flood, C. T.; Fayne, D.; Williams, D. C.; Meegan, M. J.; Lloyd, D. G. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. J. Med. Chem., 2009, 52, 2177-2180
154. Florent, J. C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Renoux, B.; Andri-anomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem., 1998, 41, 3572-3581 (Pubitemid 28449340)
155. Stan, A. C.; Radu, D. L.; Casares, S.; Bona, C. A.; Brumeanu, T. D. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen. Cancer Res., 1999, 59, 115-121
156. Geney, R.; Chen, J.; Ojima, I. Recent advances in the new generation taxane anticancer agents. Med. Chem., 2005, 1, 125-139
157. Oflazoglu, E.; Stone, I. J.; Gordon, K.; Wood, C. G.; Repasky, E. A.; Grewal, I. S.; Law, C. L.; Gerber, H. P. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res., 2008, 14, 6171-6180
158. Guillemard, V.; Saragovi, H. U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res., 2001, 61, 694-699
159. Lambert, J. M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol., 2005, 5, 543-549 (Pubitemid 41258574)
160. Safavy, A.; Bonner, J. A.; Waksal, H. W.; Buchsbaum, D. J.; Gillespie, G. Y.; Khazaeli, M. B.; Arani, R.; Chen, D. T.; Carpenter, M.; Raisch, K. P. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug. Chem., 2003, 14, 302-310
161. Safavy, A.; Raisch, K. P.; Khazaeli, M. B.; Buchsbaum, D. J.; Bonner, J. A. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem., 1999, 42, 4919-4924